Skip to search formSkip to main contentSkip to account menu

BMS-275291

Known as: D2163, N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide, REBIMASTAT 
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
When a tumor progresses it requires the nutrition and oxygen to foster uninterrupted cell division, a characteristic feature of… 
2008
2008
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… 
2008
2008
8054 Background: Outcomes in lung cancer may differ by sex, with some studies reporting longer survival in women. Increased… 
2004
2004
Tumor necrosis factor (TNF)is a well validated therapeutic target for the treatment of rheumatoid arthritis. TNFis initially… 
2003
2003
as well as TGF (cid:1) , and hidden integrin-binding sites on the ECM fragments are exposed, triggering integrin signaling, which… 
Review
2001
Review
2001
This chapter aims to provide a historical perspective of the Chiroscience matrix metalloproteinase inhibitor (MMPI) program…